Expertise in
25
conditions

Dr. Aref A. Al-Kali

Hematology
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
20 Years of Experience
Expertise in
25
conditions
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 

Overview

Aref Al-Kali is a Hematologist practicing medicine in Rochester, Minnesota. He has been practicing medicine for over 20 years.

Dr. Al-Kali is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 263 peer reviewed articles and participating in 9 clinical trials. Dr. Al-Kali is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Mayo Clinic Health System In Red Wing
Mayo Clinic Health System - Albert Lea And Austin
Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MN - Cancer Hematology
200 1st St SW, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: Sabatolimab, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drugs: Insulin-Like Growth Factor, Methotrexate
Study Phase: Phase 1/Phase 2
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Enrollment Status: Completed
Publish Date: October 30, 2019
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation
Enrollment Status: Terminated
Publish Date: August 07, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 8 Less Clinical Trials

263 Total Publications

Clinics and Clicks: Optimizing Hematology Care Delivery and Workflows in the Digital Era.
Clinics and Clicks: Optimizing Hematology Care Delivery and Workflows in the Digital Era.
Journal: JCO oncology practice
Published: August 07, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ayalew Tefferi is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Tefferi is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenectomy, and Bone Marrow Transplant. Dr. Tefferi is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Dispenzieri is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Dispenzieri is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, POEMS Syndrome, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dispenzieri is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Morie Gertz is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Gertz is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Transplant, and Tissue Biopsy. Dr. Gertz is currently accepting new patients.

Frequently Asked Questions about Dr. Aref A. Al-Kali

How do I make an appointment with Dr. Aref A. Al-Kali?

You can book an appointment with Dr. Aref A. Al-Kali by calling their office at 507-923-2592. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aref A. Al-Kali a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aref A. Al-Kali is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aref A. Al-Kali specialize in?

While Dr. Aref A. Al-Kali is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Aref A. Al-Kali participate in research or clinical trials?

Yes. Dr. Aref A. Al-Kali has published 263 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Aref A. Al-Kali's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aref A. Al-Kali accept my insurance?

Dr. Aref A. Al-Kali accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 507-923-2592 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Al-Kali's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 14 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile